Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab Treatment in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study

INTRODUCTION: Drug retention is particularly relevant to assess long-term treatments. This real-world study mainly aimed to describe 1-year retention rate (RR) of subcutaneously administered tocilizumab (TCZ-SC) in patients with moderate to severe active rheumatoid arthritis (RA). METHODS: This non-...

Descripción completa

Detalles Bibliográficos
Autores principales: Hilliquin, Pascal, Barnetche, Thomas, Baillet, Athan, Flipo, René-Marc, Lespessailles, Eric, Roux, Christian, Fardellone, Patrice, Gilbert-Marceau, Anika, Idier, Isabelle, Constantin, Arnaud, Shipley, Emilie, Baudens, Guy, Saraux, Alain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991027/
https://www.ncbi.nlm.nih.gov/pubmed/33216287
http://dx.doi.org/10.1007/s40744-020-00253-0
_version_ 1783669172255850496
author Hilliquin, Pascal
Barnetche, Thomas
Baillet, Athan
Flipo, René-Marc
Lespessailles, Eric
Roux, Christian
Fardellone, Patrice
Gilbert-Marceau, Anika
Idier, Isabelle
Constantin, Arnaud
Shipley, Emilie
Baudens, Guy
Saraux, Alain
author_facet Hilliquin, Pascal
Barnetche, Thomas
Baillet, Athan
Flipo, René-Marc
Lespessailles, Eric
Roux, Christian
Fardellone, Patrice
Gilbert-Marceau, Anika
Idier, Isabelle
Constantin, Arnaud
Shipley, Emilie
Baudens, Guy
Saraux, Alain
author_sort Hilliquin, Pascal
collection PubMed
description INTRODUCTION: Drug retention is particularly relevant to assess long-term treatments. This real-world study mainly aimed to describe 1-year retention rate (RR) of subcutaneously administered tocilizumab (TCZ-SC) in patients with moderate to severe active rheumatoid arthritis (RA). METHODS: This non-interventional, prospective, multicenter study (NCT02608112) was conducted in patients with RA initiating TCZ-SC treatment, with an 18-month follow-up. RR was estimated at month 12 in the overall population and baseline subgroups (combination with a conventional synthetic disease-modifying antirheumatic drug (csDMARD) or not, age, body mass index, methotrexate dose), using the Kaplan–Meier method. Patient compliance to TCZ-SC was described using the 5-item Compliance Questionnaire for Rheumatology (CQR5). RESULTS: At inclusion 75% of the 285 analyzed patients were women, mean RA duration was 9 ± 9 years, previous RA treatments included biological agents (63%) and/or csDMARDs (94%), mean Disease Activity Score 28 joints-Erythrocyte Sedimentation Rate (DAS28-ESR) was 4.8 ± 1.2. TCZ-SC RR at month 12 was estimated to be 64% (95% CI 58%–69%) with no statistical differences between subgroups. Clinical results improved with TCZ-SC; the proportion of patients treated with combined glucocorticoids decreased from 49% to 22% at month 12. At each follow-up time, at least 80% of patients were high adherers to TCZ-SC (at least 80% of theoretical injections). Among the 286 patients with at least one TCZ-SC injection, 25 patients (9%) experienced serious adverse events related to TCZ-SC with no differences according to patient age. CONCLUSIONS: This real-world study corroborates the RR at month 12 previously shown in interventional studies on TCZ-SC. Our data suggest there are no differences according to patient’s profile (age, BMI), methotrexate doses, and TCZ-SC use. TRIAL REGISTRATION: NCT02608112.
format Online
Article
Text
id pubmed-7991027
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-79910272021-04-16 Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab Treatment in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study Hilliquin, Pascal Barnetche, Thomas Baillet, Athan Flipo, René-Marc Lespessailles, Eric Roux, Christian Fardellone, Patrice Gilbert-Marceau, Anika Idier, Isabelle Constantin, Arnaud Shipley, Emilie Baudens, Guy Saraux, Alain Rheumatol Ther Original Research INTRODUCTION: Drug retention is particularly relevant to assess long-term treatments. This real-world study mainly aimed to describe 1-year retention rate (RR) of subcutaneously administered tocilizumab (TCZ-SC) in patients with moderate to severe active rheumatoid arthritis (RA). METHODS: This non-interventional, prospective, multicenter study (NCT02608112) was conducted in patients with RA initiating TCZ-SC treatment, with an 18-month follow-up. RR was estimated at month 12 in the overall population and baseline subgroups (combination with a conventional synthetic disease-modifying antirheumatic drug (csDMARD) or not, age, body mass index, methotrexate dose), using the Kaplan–Meier method. Patient compliance to TCZ-SC was described using the 5-item Compliance Questionnaire for Rheumatology (CQR5). RESULTS: At inclusion 75% of the 285 analyzed patients were women, mean RA duration was 9 ± 9 years, previous RA treatments included biological agents (63%) and/or csDMARDs (94%), mean Disease Activity Score 28 joints-Erythrocyte Sedimentation Rate (DAS28-ESR) was 4.8 ± 1.2. TCZ-SC RR at month 12 was estimated to be 64% (95% CI 58%–69%) with no statistical differences between subgroups. Clinical results improved with TCZ-SC; the proportion of patients treated with combined glucocorticoids decreased from 49% to 22% at month 12. At each follow-up time, at least 80% of patients were high adherers to TCZ-SC (at least 80% of theoretical injections). Among the 286 patients with at least one TCZ-SC injection, 25 patients (9%) experienced serious adverse events related to TCZ-SC with no differences according to patient age. CONCLUSIONS: This real-world study corroborates the RR at month 12 previously shown in interventional studies on TCZ-SC. Our data suggest there are no differences according to patient’s profile (age, BMI), methotrexate doses, and TCZ-SC use. TRIAL REGISTRATION: NCT02608112. Springer Healthcare 2020-11-20 /pmc/articles/PMC7991027/ /pubmed/33216287 http://dx.doi.org/10.1007/s40744-020-00253-0 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Original Research
Hilliquin, Pascal
Barnetche, Thomas
Baillet, Athan
Flipo, René-Marc
Lespessailles, Eric
Roux, Christian
Fardellone, Patrice
Gilbert-Marceau, Anika
Idier, Isabelle
Constantin, Arnaud
Shipley, Emilie
Baudens, Guy
Saraux, Alain
Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab Treatment in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study
title Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab Treatment in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study
title_full Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab Treatment in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study
title_fullStr Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab Treatment in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study
title_full_unstemmed Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab Treatment in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study
title_short Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab Treatment in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study
title_sort real-world 1-year retention rate of subcutaneous tocilizumab treatment in patients with moderate to severe active rheumatoid arthritis: tandem study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991027/
https://www.ncbi.nlm.nih.gov/pubmed/33216287
http://dx.doi.org/10.1007/s40744-020-00253-0
work_keys_str_mv AT hilliquinpascal realworld1yearretentionrateofsubcutaneoustocilizumabtreatmentinpatientswithmoderatetosevereactiverheumatoidarthritistandemstudy
AT barnetchethomas realworld1yearretentionrateofsubcutaneoustocilizumabtreatmentinpatientswithmoderatetosevereactiverheumatoidarthritistandemstudy
AT bailletathan realworld1yearretentionrateofsubcutaneoustocilizumabtreatmentinpatientswithmoderatetosevereactiverheumatoidarthritistandemstudy
AT fliporenemarc realworld1yearretentionrateofsubcutaneoustocilizumabtreatmentinpatientswithmoderatetosevereactiverheumatoidarthritistandemstudy
AT lespessailleseric realworld1yearretentionrateofsubcutaneoustocilizumabtreatmentinpatientswithmoderatetosevereactiverheumatoidarthritistandemstudy
AT rouxchristian realworld1yearretentionrateofsubcutaneoustocilizumabtreatmentinpatientswithmoderatetosevereactiverheumatoidarthritistandemstudy
AT fardellonepatrice realworld1yearretentionrateofsubcutaneoustocilizumabtreatmentinpatientswithmoderatetosevereactiverheumatoidarthritistandemstudy
AT gilbertmarceauanika realworld1yearretentionrateofsubcutaneoustocilizumabtreatmentinpatientswithmoderatetosevereactiverheumatoidarthritistandemstudy
AT idierisabelle realworld1yearretentionrateofsubcutaneoustocilizumabtreatmentinpatientswithmoderatetosevereactiverheumatoidarthritistandemstudy
AT constantinarnaud realworld1yearretentionrateofsubcutaneoustocilizumabtreatmentinpatientswithmoderatetosevereactiverheumatoidarthritistandemstudy
AT shipleyemilie realworld1yearretentionrateofsubcutaneoustocilizumabtreatmentinpatientswithmoderatetosevereactiverheumatoidarthritistandemstudy
AT baudensguy realworld1yearretentionrateofsubcutaneoustocilizumabtreatmentinpatientswithmoderatetosevereactiverheumatoidarthritistandemstudy
AT sarauxalain realworld1yearretentionrateofsubcutaneoustocilizumabtreatmentinpatientswithmoderatetosevereactiverheumatoidarthritistandemstudy